Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Alumis Q3 2026 Results: Net Loss of $94.9M, Loss Narrows

Alumis Inc. reported total assets of $488.7 million as of September 30, 2026, supported by a significant increase in marketable securities following its IPO. The company is focused on the development of envudeucitinib (envu) for plaque psoriasis, with plans to submit a New Drug Application by the end of 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.92.1
Profit before tax-94.9-110.8
Net income-94.9-110.8
EPS (diluted, $ a share)$-0.73$-1.06

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-7.7%
Source

10-Q filed with the SEC, NASDAQ: ALMS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Alumis Inc.: key numbers

Share price
$5.14Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Alumis Inc.

All →
4:11 PM ET 8-K
Financial Results

Alumis Financial Results

Alumis Inc. reported third quarter 2026 financial results and confirmed it remains on track to submit a New Drug Application (NDA) for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026. The company ended the quarter with $344.4 million in cash and cash equivalents, which is expected to fund operations into 2027.

Term
Q3 2026

“Each additional readout from the ONWARD program has strengthened the consistent body of evidence supporting envudeucitinib’s highly competitive profile in moderate-to-severe plaque psoriasis. The new data presented in October showed early and durable improvement across scalp disease severity, itch resolution, and quality of life measures, building on a 54% PASI 100 response rate observed at 48 weeks of treatment. Our fourth-quarter 2026 NDA submission remains on track.”

Martin Babler, President and Chief Executive Officer of Alumis

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.